Originally presented: Sept. 12, 2024
In this “Future Direction of Laboratory Medicine” webinar, Maggie DiGuardo, M.D., and Justin Juskewitch, M.D., Ph.D., will review the current knowledge regarding sickle cell disease from its genetic cause to the myriads of effects it can have for affected individuals. Through the lens of a clinical case study, they will describe the current treatment modalities available for long-term management of patients with sickle cell disease. The presenters will then explore the new gene therapy-based treatments for sickle cell disease and the clinical trials that supported the recent FDA approval.
Maggie DiGuardo, M.D.
Assistant Professor of Laboratory Medicine and Pathology
Division of Transfusion Medicine
Mayo Clinic, Rochester, Minnesota
Justin Juskewitch, M.D., Ph.D.
Assistant Professor of Laboratory Medicine and Pathology
Division of Transfusion Medicine
Mayo Clinic, Rochester, Minnesota
Upon completion of this activity, participants should be able to:
This webinar is appropriate for laboratory leaders, healthcare providers, and other laboratory personnel who are interested in innovations and the future direction of lab medicine.
The following types of credit are offered for this event:
Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.
Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for General (Hematology) credit. This program has been approved for 1.0 contact hour.
1. Watch the video.
2. Complete the posttest and evaluation that launches immediately following the video.
3. Generate and print your certificate(s).
Level of instruction for this program is intermediate.
Credit for this recording expires on 9/12/2026.
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.
Contact us: mcleducation@mayo.edu